Key result
Fibromyalgia was associated with significantly higher total COMPASS 31 scores compared to healthy controls (37.2 vs 9.5; p<0.00000001), indicating greater autonomic dysfunction.
Why the study?
Although the COMPASS questionnaire detects autonomic dysfunction in fibromyalgia, it was unknown whether the refined, abbreviated 31-item version (COMPASS 31) can assess autonomic function changes and correlate with FIQR scores.
Does the COMPASS 31 questionnaire detect autonomic dysfunction in patients with fibromyalgia compared to healthy controls?
Case-Control (n=51)
Does the COMPASS 31 questionnaire detect autonomic dysfunction in patients with fibromyalgia compared to healthy controls?
Absolute Event Rate: 37.2% vs 9.5%
p-value: p=<0.00000001
The COMPASS 31 questionnaire effectively identifies and quantifies non-pain autonomic dysfunction symptoms in patients with fibromyalgia.
COMPASS 31 may aid autonomic symptom assessment in fibromyalgia; hypothesis-generating and requires prospective validation before clinical adoption.
Background: It has been shown that autonomic dysfunction in fibromyalgia can be assessed by the Composite Autonomic Symptom Score (COMPASS) questionnaire. More recently, a refined and much abbreviated 31-item version of the questionnaire has been developed, the COMPASS 31. Objectives: First, to determine whether the COMPASS 31 can assess changes in autonomic function in fibromyalgia. Second, to assess whether the COMPASS 31 values in fibromyalgia patients are positively correlated with scores on the Revised Fibromyalgia Impact Questionnaire (FIQR). Method: A cross-sectional, case-controlled study was carried out with 25 fibromyalgia patients and 26 healthy controls. Results: The two groups were matched for age, sex and ethnicity, but not for body mass index (BMI). The total mean (standard error) COMPASS 31 for the fibromyalgia patients, 37.2 (1.8), differentiated the patients from the controls (9.5 (1.4); p < 0.00000001). The scores were greater in the fibromyalgia patients across all COMPASS 31 autonomic domains, namely orthostatic intolerance (p < 0.00000001), and vasomotor (p < 0.0001), secretomotor (p < 0.000001), gastrointestinal (p < 0.000001), bladder (p < 0.00001) and pupillomotor functions (p < 0.00000001). The total COMPASS 31 values were positively correlated with FIQR scores (rs = 0.45, p < 0.05). General linear modelling of the COMPASS 31 scores showed that only group status (fibromyalgia or control) was significant (p = 3.4 × 10-16), with age, sex and BMI being non-significant. Conclusion: This study confirms that non-pain autonomic dysfunction symptoms occur in fibromyalgia and can be assessed with the COMPASS 31.
No takes yet. Share an insight, caveat, or question.
Puri et al. (2021) conducted a case-control in Fibromyalgia (n=51). Fibromyalgia vs. Healthy controls was evaluated on Total COMPASS 31 score (p=<0.00000001). Fibromyalgia was associated with significantly higher total COMPASS 31 scores compared to healthy controls (37.2 vs 9.5; p<0.00000001), indicating greater autonomic dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: